A
MRNA icon

AustralianSuper’s Moderna MRNA Stock Holding History

AustralianSuper’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,584
Closed -$690K – 243
2024
Q4 		$690K Buy
16,584
+2,077
+14% +$99.3K ﹤0.01% 208
2024
Q3 		$970K Buy
14,507
+3,084
+27% +$283K ﹤0.01% 213
2024
Q2 		$1.36M Hold
11,423
– – 0.01% 193
2024
Q1 		$1.21M Hold
11,423
– – 0.01% 199
2023
Q4 		$1.14M Sell
11,423
-40,587
-78% -$3.41M 0.01% 221
2023
Q3 		$5.37M Sell
52,010
-78,600
-60% -$8.77M 0.03% 143
2023
Q2 		$15.9M Sell
130,610
-470,826
-78% -$62.8M 0.1% 121
2023
Q1 		$92.4M Sell
601,436
-165,376
-22% -$27.3M 0.56% 48
2022
Q4 		$137M Buy
766,812
+54,237
+8% +$8.87M 0.91% 30
2022
Q3 		$84.3M Buy
712,575
+68,855
+11% +$10.4M 0.6% 43
2022
Q2 		$92M Buy
643,720
+409,891
+175% +$58.6M 0.57% 46
2022
Q1 		$40.3M Buy
+233,829
New +$39.4M 0.22% 76

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AustralianSuper's MRNA Position: Q1 2025 in Review

AustralianSuper sold out of Moderna (MRNA) in Q1 2025, closing a stake of 16,584 shares — an estimated $690K sold.

AustralianSuper first reported a position in MRNA in Q1 2022 and held it in 12 quarters. The position peaked at $137M in Q4 2022. 694 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • AustralianSuper reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • AustralianSuper sold 16,584 Moderna shares in Q1 2025, an estimated $690K.
  • AustralianSuper first reported a position in Moderna in Q1 2022 and held it in 12 quarters.
  • AustralianSuper's Moderna position peaked at $137M in Q4 2022.
  • 694 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on AustralianSuper's 13F filing for Q1 2025, filed 5 May 2025.